ClinicalTrials.gg
Not yet recruitingNCT06919861Updated Aug 3, 2026

Pharmacokinetics, Pharmacodynamics, and Safety of NANOKINE Compared With Eprex 4000 U in Healthy Volunteers

A Phase 1 interventional study of Erythropoietin alfa and Erythropoietin alfa in Pharmacokinetics and Pharmacodynamics in Healthy Volunteers, sponsored by Nanogen Pharmaceutical Biotechnology Joint Stock Company. Not yet recruiting. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Nanogen Pharmaceutical Biotechnology Joint Stock Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This clinical trial aims to compare the pharmacokinetic (PK), pharmacodynamic (PD) parameters, and safety between Nanokine of Nanogen Pharmaceutical Joint Stock Company and Eprex® of Janssen Cilag Ltd on healthy male volunteers.

The biosimilarity of erythropoietin (EPO) between Nanokine (test) and Eprex® (comparator) was evaluated in a randomized, two-treatment, two-period, crossover, single-dose study.

Subjects received a 4,000 IU subcutaneous dose of either formulation, followed by the alternate after a 28-day washout.

Key pharmacokinetic (PK) parameters, Cmax and AUCinf, were assessed, with geometric mean ratios/GMR (90% CI) falling within the regulatory range (0.80-1.25). Pharmacodynamic (PD) marker (reticulocyte count) need to show comparable effects.

Safety evaluation (adverse events and serious adverse events, other safety assessments such as vital signs, testing, and examination) supports their interchangeability in clinical use.

Read the detailed description

Erythropoietin (EPO) is a glycoprotein hormone essential for red blood cell (RBC) formation, primarily produced in the kidneys. Recombinant human erythropoietin (rHuEPO) or erythropoiesis-stimulating agents (ESAs) are used to treat anemia in chronic renal failure, chemotherapy-induced anemia, and to reduce transfusion needs in surgery.

Nanokine, currently considered as a follow-on biological product of Eprex® developed by Nanogen Biopharmaceutical JSC, is produced in CHO cells. This study evaluates the bioequivalence of Nanokine and Eprex® in healthy volunteers, comparing pharmacokinetics (PK), pharmacodynamics (PD), and safety.

A randomized, open-label, single-dose, two-sequence crossover trial is conducted in 44 healthy male volunteers (aged 19-45 years, BMI 18.0-28.0 kg/m²). Participants received a 4,000 IU subcutaneous injection of either Eprex® or Nanokine, followed by the alternate after a 28-day washout. Blood samples for PK analysis were taken at multiple time points up to 144 hours postdose, while PD markers (reticulocytes) were measured up to 312 hours postdose.

The purpose of this clinical study is to evaluate and compare the pharmacokinetics, pharmacodynamics, and safety profile of NANOKINE (manufactured by Nanogen Pharmaceutical Biotechnology Joint Stock Company) with Eprex 4000 U (manufactured by Cilag AG).

This is a randomized, two-treatment, two-period, crossover study involving a single-dose subcutaneous injection administered to healthy volunteers.

Participants will undergo a comprehensive screening process to ensure they are in good health, meet the required age range of 18 to 45 years, and fall within the specified body weight and body mass index (BMI) criteria. Eligible subjects will be randomly assigned to receive the study treatments across two distinct periods, separated by a washout phase, to evaluate how each product behaves in the body and to assess their overall safety and tolerability.

Pharmacokinetics (PK) Statistical Hypotheses:

  • Null Hypothesis (H0): The 90% confidence interval of the geometric mean ratio (GMR) between NANOKINE and Eprex 4000 U for the log-transformed data of AUC0-t and Cmax falls outside the bioequivalence limits of 80.00% to 125.00%.
  • Alternative Hypothesis (H1): The 90% confidence interval of the GMR falls within the limits of 80.00% to 125.00% for the log-transformed data of both AUC0-t and Cmax, thereby demonstrating pharmacokinetic equivalence between the two formulations.

Pharmacodynamics (PD) Statistical Hypotheses:

  • Null Hypothesis (H0): The 90% confidence interval of the geometric mean ratio (GMR) between NANOKINE and Eprex 4000 U for the log-transformed data of AUC0-t and Cmax of reticulocyte (RET) count falls outside the bioequivalence limits of 80.00% to 125.00%.
  • Alternative Hypothesis (H1): The 90% confidence interval of the GMR falls within the limits of 80.00% to 125.00% for the log-transformed data of both AUC0-t and Cmax of reticulocyte (RET) count, thereby demonstrating pharmacodynamic equivalence between the two formulations.

This study is conducted at the Center for Clinical Pharmacology, Hanoi Medical University, in accordance with the Vietnam Biomedical Research, Ethics, and Regulatory Guidelines.

02

Conditions studied

  • Pharmacokinetics and Pharmacodynamics in Healthy Volunteers
03

In context

Lead sponsor

Nanogen Pharmaceutical Biotechnology Joint Stock Company is the lead sponsor of 11 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male, aged 18 to 45 years.
  2. Body weight 50 kg - 70 kg, 18 - 28 kg/m², calculated per Metropolitan Index 1983 for adults.
  3. At the time of screening, the subject is determined to be healthy by the investigator through a general clinical examination.
  4. Laboratory test results for , hematology and biochemistry (fasting glucose, urea, , ALT, creatinine) are within normal limits or assessed by the investigator as normal/eligible for study participation.
  5. Screening test results:

    • 125-175 g/L;
    • Vitamin B12 200-300 pg/mL;
    • Ferritin 22-400 ng/mL;
    • Transferrin 200-360 mg/dL;
    • Albumin 35-52 g/L;
    • Reticulocytes, red blood cells, and within normal range;
    • Negative urine drug screen;
    • Negative , anti- and .
  6. Voluntarily participates in the study and has signed the form.

Exclusion criteria

Exclusion Criteria:

  1. Lacks civil act capacity.
  2. History of severe allergic reaction or anaphylaxis to biological products.
  3. Use of Erythropoiesis Stimulating Agents (ESAs) or immunoglobulins within 3 months prior to screening.
  4. History of seizures, epilepsy, or current disorders of the cardiovascular, respiratory, hepatic, renal, gastrointestinal, immune, hematologic, endocrine, nervous system, or psychiatric illness (as determined by the examining physician).
  5. Recent illness within 2 weeks prior to screening (based on medical history and clinical examination).
  6. History of blood loss >450 mL or blood donation within 28 days prior to the first scheduled dose.
  7. History of illicit drug use.
  8. Recent history of alcohol abuse (defined as regular alcohol consumption within 6 months prior to screening, with average weekly intake >21 units/week. One unit equals 8 g ethanol, equivalent to: 240 mL (half a glass) of beer, or 100 mL (1 glass) of wine, or 25 mL (1 shot) of spirits).
  9. Recent history of tobacco abuse (defined as smoking on average >10 cigarettes/day within 3 months prior to screening, or inability to abstain from smoking throughout the study period).
  10. Excessive caffeine consumption (more than 5 cups of coffee per day).
  11. Special dietary habits or inability to consume meals provided by the study site.
  12. Currently participating in another clinical study, or has participated in a clinical study with another product within the last 3 months.
  13. Planning to conceive during the study period or unwilling to use throughout the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Nanokine 4000 IU

    Nanokine 4000 IU, prefilled syringe, subcutaneous injection. Nanokine 4000 IU will be transported and handed over to the Study Center by the Sponsor. Nanokine 4000 IU should be stored in a refrigerator of 2-8°C.

    Biological: Erythropoietin alfa

  • Active comparator
    Eprex 4000 U

    Eprex 4000 U, pre-closed syringe, subcutaneous injection. Eprex 4000 U will be transported and handed over directly to the Study Center by the supplier (with a contract with the Sponsor). Eprex 4000 U should be stored in a refrigerator of 2- 8 °C.

    Biological: Erythropoietin alfa

Interventions

  • Experimental drug: Nanokine 4000 IU, prefilled syringe, subcutaneous injection Manufactured: Nanogen Biopharmaceutical JSC. Arm 1 (22 volunteers): Nanokineinjection 4000 IU will be administered subcutaneously on Day 1, and after a 28-day washout period, Eprex® injection 4000 IU will be administered subcutaneously on Day 29.

    Also known as: Nanokine

  • Comparator drug: Eprex® 4000 IU, prefilled syringe, subcutaneous injection Manufactured: Janssen-Cilag Ltd Arm 2 (22 volunteers): Eprex® injection 4000 IU will be administered subcutaneously on Day 1, and after a 28-day washout period, Eprex injection 4000 IU will be administered subcutaneously on Day 29. Total: 44 participants will be recruited in the trial.

    Also known as: Eprex

06

What researchers measure

Primary outcomes

  1. AUC0-t

    Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t)

    Time frame: Pre-dose (30, 20, and 10 minutes before administration) and post-dose (30 minutes, 3, 6, 9, 12, 14, 15, 24, 30, 48, 72, 96, 120, and 144 hours after administration)

  2. Cmax

    Peak plasma concentration

    Time frame: Pre-dose (30, 20, and 10 minutes before injection) and post-dose (30 minutes, 3, 6, 9, 12, 14, 15, 24, 30, 48, 72, 96, 120, and 144 hours after injection).

  3. AUC0-t of RET

    Area Under the Effect-Time Curve of Reticulocyte Count (AUC0-t of RET)

    Time frame: Pre-dose (10 minutes before administration) and post-dose (12, 24, 48, 72, 96, 120, 144, 168, 216, and 312 hours after administration)

  4. Cmax of RET

    Maximum Observed Effect of Reticulocyte Count (Cmax of RET)

    Time frame: Pre-dose (10 minutes before administration) and post-dose (12, 24, 48, 72, 96, 120, 144, 168, 216, and 312 hours after administration)

Secondary outcomes

  1. AUC0-inf

    Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf)

    Time frame: Pre-dose (30, 20, and 10 minutes before administration) and post-dose (30 minutes, 3, 6, 9, 12, 14, 15, 24, 30, 48, 72, 96, 120, and 144 hours after administration)

  2. Tmax

    Time to Maximum Observed Plasma Concentration (Tmax)

    Time frame: Pre-dose (30, 20, and 10 minutes before administration) and post-dose (30 minutes, 3, 6, 9, 12, 14, 15, 24, 30, 48, 72, 96, 120, and 144 hours after administration)

  3. T1/2

    Plasma Elimination Half-Life (T1/2)

    Time frame: Pre-dose (30, 20, and 10 minutes before administration) and post-dose (30 minutes, 3, 6, 9, 12, 14, 15, 24, 30, 48, 72, 96, 120, and 144 hours after administration)

  4. CL.obs

    Apparent Clearance (CL.obs)

    Time frame: Pre-dose (30, 20, and 10 minutes before administration) and post-dose (30 minutes, 3, 6, 9, 12, 14, 15, 24, 30, 48, 72, 96, 120, and 144 hours after administration)

  5. Vz.obs

    Apparent Volume of Distribution (Vz.obs)

    Time frame: Pre-dose (30, 20, and 10 minutes before administration) and post-dose (30 minutes, 3, 6, 9, 12, 14, 15, 24, 30, 48, 72, 96, 120, and 144 hours after administration).

  6. Lambda.z

    Terminal Elimination Rate Constant (Lambda.z)

    Time frame: Pre-dose (30, 20, and 10 minutes before administration) and post-dose (30 minutes, 3, 6, 9, 12, 14, 15, 24, 30, 48, 72, 96, 120, and 144 hours after administration)

  7. RBC Count

    Red Blood Cell (RBC) Count

    Time frame: Pre-dose (10 minutes before administration) and post-dose (12, 24, 48, 72, 96, 120, 144, 168, 216, and 312 hours after administration)

  8. Hb

    Hemoglobin (Hb)

    Time frame: Pre-dose (10 minutes before administration) and post-dose (12, 24, 48, 72, 96, 120, 144, 168, 216, and 312 hours after administration)

  9. Adverse events

    Adverse events (AE); Serious adverse events (SAE); Other safety assessments such as vital signs, testing, and examination.

    Time frame: Baseline to 312 hours after the crossover dose

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2025
First posted
Apr 9, 2025
StartEst.
Sep 2026
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06919861
Lead sponsor
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Responsible party
Sponsor
First posted
Apr 9, 2025
Start date
Sep 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Aug 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion